Akorn Company Profile (NASDAQ:AKRX)

Akorn trades on the NASDAQ under the ticker symbol "AKRX."

Akorn, Inc. (NASDAQ:AKRX) issued its quarterly earnings results on Thursday, August, 4th. The company reported $0.58 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.55 by $0.03. The firm earned $280.70 million during the quarter, compared to analysts' expectations of $272.99 million. Akorn had a return on equity of 21.31% and a net margin of 12.15%. The firm's revenue was up 27.1% compared to the same quarter last year. View Akorn's Earnings History.

11 brokerages have issued twelve-month target prices for Akorn's stock. Their forecasts range from $20.00 to $40.00. On average, they anticipate Akorn's stock price to reach $29.13 in the next year. View Analyst Ratings for Akorn.

Here are some recent quotes from research analysts about Akorn stock:

• 1. According to Zacks Investment Research, "Akorn, Inc. manufactures and markets diagnostic and therapeutic pharmaceuticals in specialty areas such as ophthalmology, rheumatology, anesthesia and antidotes, among others. They also market ophthalmic surgical instruments and related products. Customers include physicians, optometrists, wholesalers, group purchasing organizations and other pharmaceutical companies. They also provide contract manufacturing services. " (8/25/2017)
• 2. Royal Bank Of Canada analysts commented, "We now see two major hurdles lifted (i) a much needed reset on 2017 EPS and (ii) greater comfort on new approvals from Decatur. From here, debate will move to whether there is enough new launch revenue to offset erosion and drive growth beyond 2017. Story is de-risked meaningfully but we are still struggling to find growth off lower base. Target down to $21... Leading into 4Q we have been concerned that Street numbers for 2017 were meaningfully too high and that new approvals were not coming from the Decatur facility. First time 2017 guidance of $1.53 to $1.72 should re-set the Street's $2.17, lowering the bar for this year, and last night's announced approvals out of Decatur assuaged concerns around facility risk. In other words, two major concerns around this stock have now been removed. We have updated our model and our 2017-19E EPS move roughly $0.30 lower but still show little growth at $1.61, $1.64 and $1.69 (but we think guidance is reasonable). The re-set reduced risk but pushes valuation to 9.3x our 2018E EBITDA which is not necessarily inexpensive against the limited growth in our model." (3/2/2017)

Akorn saw a increase in short interest during the month of August. As of August 31st, there was short interest totalling 19,291,494 shares, an increase of 23.6% from the August 15th total of 15,605,371 shares. Based on an average daily volume of 3,412,104 shares, the short-interest ratio is presently 5.7 days. Currently, 20.8% of the shares of the company are sold short.

Some companies that are related to Akorn include Dr. Reddy's Laboratories Ltd (RDY), Catalent (CTLT), Patheon NV (PTHN), Valeant Pharmaceuticals International (VRX), Taro Pharmaceutical Industries (TARO), Opko Health (OPK), Hikma Pharmaceuticals Plc (HIK), BTG plc (BTG), Amicus Therapeutics (FOLD), Corcept Therapeutics Incorporated (CORT), Horizon Pharma PLC (HZNP), Theravance Biopharma (TBPH), Cambrex Corporation (CBM), Akcea Therapeutics (AKCA), Impax Laboratories (IPXL), Emergent Biosolutions (EBS), Innoviva (INVA) and Pacira Pharmaceuticals (PCRX).

Akorn's management team includes the folowing people:

• John N. Kapoor Ph.D., Chairman of the Board
• Rajat Rai, Chief Executive Officer
• Duane A. Portwood, Chief Financial Officer, Executive Vice President
• Bruce Kutinsky Ph.D., Chief Operating Officer
• Joseph P. Bonaccorsi, Executive Vice President, General Counsel, Secretary
• Jonathon Kafer, Executive Vice President - Sales and Marketing
• Steven Joseph Lichter, Executive Vice President - Pharmaceutical Operations
• Randall E. Pollard, Senior Vice President, Chief Accounting Officer, Corporate Controller
• Brian Tambi, Director
• Kenneth S. Abramowitz, Independent Director

Akorn's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.44%), Vanguard Group Inc. (5.70%), FMR LLC (3.48%), Pentwater Capital Management LP (3.15%), CNH Partners LLC (2.77%) and State Street Corp (2.28%). Company insiders that own Akorn stock include Alan D Weinstein, Brian Tambi, Bruce Kutinsky, Joseph Bonaccorsi, Kenneth Abramowitz and Ronald M Johnson. View Institutional Ownership Trends for Akorn.

Akorn's stock was sold by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Kornitzer Capital Management Inc. KS, LSV Asset Management, Oak Ridge Investments LLC, Ameriprise Financial Inc., Parametric Portfolio Associates LLC, New York State Common Retirement Fund and Russell Investments Group Ltd.. Company insiders that have sold Akorn stock in the last year include Brian Tambi and Bruce Kutinsky. View Insider Buying and Selling for Akorn.

Akorn's stock was purchased by a variety of institutional investors in the last quarter, including Pentwater Capital Management LP, CNH Partners LLC, OMERS ADMINISTRATION Corp, Renaissance Technologies LLC, FMR LLC, PSquared Asset Management AG, City Financial Investment Co Ltd and Chicago Capital Management LLC. View Insider Buying and Selling for Akorn.

Shares of Akorn can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Akorn stock can currently be purchased for approximately $33.06.